Philip Mease, MD

Rheumatologist, Director of Rheumatology Research, Clinical Professor Director of Rheumatology Research Swedish Medical Center/Providence-St Joseph Health
Swedish Medical Center/Providence St. Joseph Health
Seattle, WA, United States

Dr. Mease received undergraduate and medical degrees from Stanford University, completed residency in internal medicine and fellowship in rheumatology at the University of Washington, directs the rheumatology research division at Swedish Medical Center/Providence St. Joseph Health and is Clinical Professor of Medicine at the University of Washington in Seattle. Major research interests include psoriatic arthritis (PsA) and spondyloarthritis (SpA). Work includes research on disease state, development of outcome measures, and determining the efficacy and safety of emerging therapies for these conditions. Authored over 600 journal articles, numerous abstracts, and book chapters. Past president, founding organizer and current treasurer of the Group for Research and Assessment of Psoriasis and PsA (GRAPPA) and member of its Collaborative Research Network (CRN) steering committee. Member of the Assessment of Spondyloarthritis international Society (ASAS) and the Spondyloarthritis Research and Treatment Network (SPARTAN). Active in the Outcome Measures in Rheumatology Clinical Trials (OMERACT) organization as co-chair of the PsA and chronic pain working groups, and steering committee member. Scientific director of PsA and SpA arms of the Consortium of Rheumatology Researchers of North America (Corrona/CorEvitas) registry. Co-chair of the PsA task force of the National Psoriasis Foundation; in 2019 awarded him a lifetime achievement award for his work in advancing the field of PsA.

Disclosure information not submitted.

Presentation(s):

• 218: JAK Inhibition: An Innovative Prescription Treatment Option for Active Ankylosing Spondylitis

  Saturday, November 12, 2022
  11:30 AM – 12:15 PM Eastern Time

• 0409: Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies

  Saturday, November 12, 2022
  1:00 PM – 3:00 PM Eastern Time

• 227: Treat PsA From The Start: Consider Otezla For Patients Who Need More Than An NSAID

  Saturday, November 12, 2022
  6:30 PM – 8:30 PM Eastern Time

• 0409: Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies

  Sunday, November 13, 2022
  9:00 AM – 9:05 AM Eastern Time

• 2151: Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial

  Sunday, November 13, 2022
  9:45 AM – 9:50 AM Eastern Time

• 1035: Efficacy of Guselkumab in Three Cohorts of Biologic-Naïve PsA Patients with Axial Involvement Defined Based on Imaging and Machine-Learning Criteria: Pooled Analysis of Two Phase 3 Studies

  Sunday, November 13, 2022
  9:00 AM – 10:30 AM Eastern Time

• 230: Network Meta-Analysis (NMA)

  Sunday, November 13, 2022
  11:30 AM – 12:15 PM Eastern Time

• 1499: The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control in Patients with Axial Spondyloarthritis: A Study from the CorEvitas PsA/SpA Registry

  Sunday, November 13, 2022
  1:20 PM – 1:25 PM Eastern Time

• 1218: Prevalence and Impact of Widespread Pain and Fibromyalgia on Measurement of Disease Severity in Psoriatic Arthritis: Lessons from the CorEvitas Registry

  Sunday, November 13, 2022
  1:00 PM – 3:00 PM Eastern Time

• 1493: Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs) in Psoriatic Arthritis: Lessons from the CorEvitas PsA/SpA Registry

  Sunday, November 13, 2022
  1:00 PM – 3:00 PM Eastern Time

• 1499: The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control in Patients with Axial Spondyloarthritis: A Study from the CorEvitas PsA/SpA Registry

  Sunday, November 13, 2022
  1:00 PM – 3:00 PM Eastern Time

• 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial

  Sunday, November 13, 2022
  3:15 PM – 3:25 PM Eastern Time

• 241: Going the Distance in Spondyloarthritis: Case Challenges in Evidence-Based Care

  Monday, November 14, 2022
  7:00 AM – 8:30 AM Eastern Time

• 2117: Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Phase 3 Randomized, Placebo-Controlled Studies

  Monday, November 14, 2022
  1:00 PM – 3:00 PM Eastern Time

• 2140: Exposure-Adjusted Incidence Rate for Adverse Events of Special Interest in Patients with Psoriatic Arthritis Treated with Apremilast

  Monday, November 14, 2022
  1:00 PM – 3:00 PM Eastern Time

• 2146: Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years

  Monday, November 14, 2022
  1:00 PM – 3:00 PM Eastern Time

• 2196: Risk Factors for Severe COVID-19 Outcomes: A Study of Immune-mediated Inflammatory Diseases, Immunomodulatory Medications, Vaccination Status, and Comorbidities in a Large US Healthcare System

  Monday, November 14, 2022
  4:15 PM – 4:25 PM Eastern Time